<<< Full experiment listing

PXD014234

PXD014234 is an original dataset announced via ProteomeXchange.

Dataset Summary
TitleAnti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma
DescriptionThe PI3K pathway is a major driver of cancer progression. However, clinical resistance to PI3K inhibition is common. IBL-302 is a novel highly specific triple PIM, PI3K and mTOR inhibitor. Screening IBL-302 in over 700 cell lines representing 47 tumor types identified neuroblastoma as a strong candidate for PIM/PI3K/mTOR inhibition. IBL-302 was more effective than single PI3K inhibition in vitro and IBL-302 treatment of neuroblastoma patient-derived xenograft (PDX) cells induced apoptosis, differentiated tumor cells, and decreased N-Myc protein levels. IBL-302 further enhanced the effect of the common cytotoxic chemotherapies cisplatin, doxorubicin, and etoposide. Global genome, proteome and phospho-proteome analyses identified crucial biological processes, including cell motility and apoptosis, targeted by IBL-302 treatment. While IBL-302 treatment alone reduced tumor growth in vivo, combination therapy with low-dose cisplatin inhibited neuroblastoma PDX growth. Complementing conventional chemotherapy treatment with PIM/PI3K/mTOR inhibition has the potential to improve clinical outcomes and reduce severe late effects in children with high-risk neuroblastoma.
HostingRepositoryPRIDE
AnnounceDate2019-07-11
AnnouncementXMLSubmission_2019-07-18_00:47:01.xml
DigitalObjectIdentifier
ReviewLevelPeer-reviewed dataset
DatasetOriginOriginal dataset
RepositorySupportUnsupported dataset by repository
PrimarySubmitterCharlotte Welinder
SpeciesList scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationListphosphorylated residue; acetylated residue; monohydroxylated residue
InstrumentQ Exactive
Dataset History
RevisionDatetimeStatusChangeLog Entry
02019-06-12 07:57:30ID requested
12019-07-11 05:28:03announced
22019-07-18 00:47:02announcedUpdated publication reference for PubMed record(s): 31310053.
Publication List
Mohlin S, Hansson K, Radke K, Martinez S, Blanco-Apiricio C, Garcia-Ruiz C, Welinder C, Esfandyari J, O'Neill M, Pastor J, von Stedingk K, Bexell D, Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma. EMBO Mol Med, 11(8):e10058(2019) [pubmed]
Keyword List
ProteomeXchange project tag: Cancer (B/D-HPP), Biology/Disease-Driven Human Proteome Project (B/D-HPP), Human Proteome Project
submitter keyword: Cisplatin, IBL-302, Neuroblastoma, Multikinase inhibition, PI3K, LC-MS/MS
Contact List
Charlotte Welinder
contact affiliationDivision of Oncology and Pathology, Dept. of Clinical Sciences Lund, Lund University, Lund, Sweden
contact emailcharlotte.welinder@med.lu.se
lab head
Charlotte Welinder
contact affiliationDept. of Oncology, Clinical Sciences, Lund University, 221 85 Lund, Sweden
contact emailcharlotte.welinder@med.lu.se
dataset submitter
Full Dataset Link List
Dataset FTP location
PRIDE project URI
Repository Record List
[+]